Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Cancer Manag Res
2019 Sep 05;11:8191-8200. doi: 10.2147/CMAR.S213572.
Show Gene links
Show Anatomy links
Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib.
Liang H
,
Ma D
,
Xu Y
,
Zhao J
,
Chen M
,
Liu X
,
Zhong W
,
Li J
,
Wang M
.
???displayArticle.abstract???
BACKGROUND: Targeted therapy is an important treatment for advanced non-small cell lung cancer (NSCLC) patients with specific genetic mutations, crizotinib can prolong survival in advanced NSCLC patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) rearrangement. We performed a retrospective analysis to investigate the association between the lactate dehydrogenase (LDH) levels and progression-free survival (PFS) in patients with EML4-ALK rearrangement NSCLC receiving treatment with crizotinib.
METHODS: Advanced (stage IIIb-IV) NSCLC patients with EML4-ALK rearrangement receiving treatment with crizotinib were enrolled between January 2007 and January 2016 at Peking Union Medical College and Cancer Hospital Chinese Academy of Medical Sciences.
RESULTS: Overall, 212 patients were enrolled. Kaplan-Meier univariate analysis showed that elevated pre-treatment LDH level (7.9 vs 14.1 months, HR =1.251, CI: 1.008-1.553, P=0.004) was significantly associated with shorter PFS, while the post-treatment mean-LDH level (13.3 vs 14.3 months, HR=1.439, 95% CI: 0.994-2.082, P=0.970) was not significantly associated with PFS. Cox proportional hazards model also identified that pre-treatment LDH level (HR=2.085, 95% CI: 1.150-3.781, P=0.016) was associated with the PFS. Logistic regression analysis showed that post-treatment LDH level was associated with creatine kinase (OR=6.712, 95% CI 3.395-13.273, P<0.01), creatine kinase isoenzyme (OR=6.297, 95% CI 2.953-13.427, P<0.01), and hemoglobin (OR=4.163, 1.741-9.956, P<0.001).
CONCLUSION: An elevated pre-treatment serum LDH level (>250 U/L) was significantly associated with shorter PFS in patients with EML4-ALK rearrangement NSCLC. Post-treatment elevated serum LDH level was not significantly associated with PFS, which related to adverse events including muscle damage and anemia.
Albain,
Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience.
1991, Pubmed
Albain,
Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience.
1991,
Pubmed
Camidge,
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
2012,
Pubmed
Chun,
Isolated central nervous system progression on Crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation?
2012,
Pubmed
Costa,
CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.
2011,
Pubmed
Costa,
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.
2015,
Pubmed
Danner,
Long-term survival is linked to serum LDH and partly to tumour LDH-5 in NSCLC.
2010,
Pubmed
Deng,
Higher pretreatment lactate dehydrogenase concentration predicts worse overall survival in patients with lung cancer.
2018,
Pubmed
Espinosa,
Serum albumin and other prognostic factors related to response and survival in patients with advanced non-small cell lung cancer.
1995,
Pubmed
Gallo,
Lactic dehydrogenase and cancer: an overview.
2015,
Pubmed
Gettinger,
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
2016,
Pubmed
Giatromanolaki,
Expression of enzymes related to glucose metabolism in non-small cell lung cancer and prognosis.
2017,
Pubmed
Hespanhol,
Survival predictors in advanced non-small cell lung cancer.
1995,
Pubmed
Inomata,
Elevated levels of plasma lactate dehydrogenase is an unfavorable prognostic factor in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer, receiving treatment with gefitinib or erlotinib.
2016,
Pubmed
Inomata,
Plasma neuron-specific enolase level as a prognostic marker in patients with non-small cell lung cancer receiving gefitinib.
2015,
Pubmed
Kim,
Prognostic model to predict outcomes in non-small cell lung cancer patients with erlotinib as salvage treatment.
2010,
Pubmed
Koukourakis,
Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis.
2003,
Pubmed
Li,
Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer.
2013,
Pubmed
Li,
Predictive value of LDH kinetics in bevacizumab treatment and survival of patients with advanced NSCLC.
2018,
Pubmed
Li,
Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors.
2011,
Pubmed
,
Echinobase
Liu,
Lactate dehydrogenase and creatine kinase as poor prognostic factors in lung cancer: A retrospective observational study.
2017,
Pubmed
Mezquita,
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
2018,
Pubmed
O'Connell,
Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy.
1986,
Pubmed
Peters,
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
2017,
Pubmed
Ramalingam,
A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1).
2015,
Pubmed
Sanders,
Exon scanning by reverse transcriptase-polymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer.
2011,
Pubmed
Sgambato,
Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
2018,
Pubmed
Shaw,
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
2013,
Pubmed
Siegel,
Cancer statistics, 2015.
2015,
Pubmed
Solomon,
First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
2014,
Pubmed
Soria,
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
2017,
Pubmed
Soussi,
Development and validation of a prognostic index for survival in non-small cell lung cancer: Results from a Tunisian cohort study.
2018,
Pubmed
Taniguchi,
Predictive Factors for Poor Progression-free Survival in Patients with Non-small Cell Lung Cancer Treated with Nivolumab.
2017,
Pubmed
Ulas,
A laboratory prognostic index model for patients with advanced non-small cell lung cancer.
2014,
Pubmed
Vander Heiden,
Understanding the Warburg effect: the metabolic requirements of cell proliferation.
2009,
Pubmed
Xie,
Targeting lactate dehydrogenase--a inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells.
2014,
Pubmed
Zhang,
Anaplastic lymphoma kinase inhibitors in non-small cell lung cancer patients with brain metastases: a meta-analysis.
2019,
Pubmed
Zhu,
A new prognostic score based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer.
2016,
Pubmed
van Zandwijk,
Prognostic factors in NSCLC. Recent experiences.
1995,
Pubmed
